Meeder Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Meeder Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-141	Closed	-$16K	–	2174
2022 Q3	$16K	Buy	+141	New	+$48	﹤0.01%	1182
2022 Q2	–	Sell	-438	Closed	-$60K	–	2505
2022 Q1	$60K	Buy	+438	New	+$372	﹤0.01%	920
2021 Q4	–	Sell	-33	Closed	-$6K	–	2503
2021 Q3	$6K	Buy	+33	New	+$72	﹤0.01%	1892
2018 Q4	–	Sell	-546	Closed	-$11K	–	1847
2018 Q3	$11K	Buy	546 +460	+535%	+$8.37K	﹤0.01%	1149
2018 Q2	$1.56K	Buy	+86	New	+$1.27K	﹤0.01%	1445
2017 Q3	–	Sell	-63	Closed	-$11K	–	1799
2017 Q2	$11K	Sell	63 -11	-15%	-$1.93K	﹤0.01%	982
2017 Q1	$9K	Buy	74 +66	+825%	+$6.92K	﹤0.01%	890
2016 Q4	$1K	Buy	+8	New	+$842	﹤0.01%	967

Other funds holding SIOX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TVWM

Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's SIOX Position: Q4 2022 in Review

Meeder Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2022, closing a stake of 141 shares — an estimated $16K sold.

Meeder Asset Management first reported a position in SIOX in Q4 2016 and held it in 8 quarters. The position peaked at $60K in Q1 2022. 37 funds tracked by Wall St. Rank hold SIOX as of Q4 2022.

Meeder Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 141 Sio Gene Therapies Inc. Common Stock shares in Q4 2022, an estimated $16K.
Meeder Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $60K in Q1 2022.
37 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.